Evidence map›Paper›PMID 37753973›Full record

ArticleAntibodies (Basel, Switzerland)2023

Characterization of N-Terminal Asparagine Deamidation and Clipping of a Monoclonal Antibody.

Jing Zhen, Jennifer Lee, Yueyang Wang, Lena McLaughlin, Fei Yang, Zhengjian Li, Jihong Wang

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jing ZhenDepartment of Analytical Sciences, U.S. Technical & Biologics Development, Horizon Therapeutics, Rockville, MD 20850, USA.ORCID 0000-0003-2666-0827
Jennifer LeeDepartment of Analytical Sciences, U.S. Technical & Biologics Development, Horizon Therapeutics, Rockville, MD 20850, USA.
Yueyang WangDepartment of Analytical Sciences, U.S. Technical & Biologics Development, Horizon Therapeutics, Rockville, MD 20850, USA.
Lena McLaughlinDepartment of Analytical Sciences, U.S. Technical & Biologics Development, Horizon Therapeutics, Rockville, MD 20850, USA.
Fei YangDepartment of Analytical Sciences, U.S. Technical & Biologics Development, Horizon Therapeutics, Rockville, MD 20850, USA.
Zhengjian LiDepartment of Analytical Sciences, U.S. Technical & Biologics Development, Horizon Therapeutics, Rockville, MD 20850, USA.ORCID 0000-0002-1941-4145
Jihong WangDepartment of Analytical Sciences, U.S. Technical & Biologics Development, Horizon Therapeutics, Rockville, MD 20850, USA.ORCID 0000-0001-9271-0218
Horizon Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study presents a novel degradation pathway of a human immunoglobulin G (IgG) molecule featuring a light chain N-terminal asparagine. We thoroughly characterize this pathway and investigate its charge profiles using cation exchange chromatography (CEX) and capillary isoelectric focusing (cIEF). Beyond the well-documented asparagine deamidation into isoaspartic acid, aspartic acid, and succinimide intermediate, a previously unreported clipping degradation pathway is uncovered. This newly identified clipped N-terminal IgG variant exhibits a delayed elution in CEX, categorized as a "basic variant", while retaining the same main peak isoelectric point (pI) in cIEF. The influence of temperature and pH on N-terminal asparagine stability is assessed across various stressed conditions. A notable correlation between deamidation percentage and clipped products is established, suggesting a potential hydrolytic chemical reaction underlying the clipping process. Furthermore, the impact of N-terminal asparagine modifications on potency is evaluated through ELISA binding assays, revealing minimal effects on binding affinity. Sequence alignment reveals homology to a human IgG with the germline gene from Immunoglobulin Lambda Variable 6-57 (IGLV6-57), which has implications for amyloid light-chain (AL) amyloidosis. This discovery of the N-terminal clipping degradation pathway contributes to our understanding of immunoglobulin light chain misfolding and amyloid fibril deposition under physiological conditions.

Indexed as

biopharmaceutical characterizationcharge profiledeamidationliquid chromatography–mass spectrometry (LC-MS)monoclonal antibody(s)N-terminal truncation

Identifiers

PMID37753973
PMCPMC10525203
OpenAlexW4386894503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.